Illumina Inc ILMN

NAS: ILMN | ISIN: US4523271090   17/09/2025
100,87 USD (-0,60%)
(-0,60%)   17/09/2025

8 september 2025 · Lancement d'Illumina® Protein Prep pour améliorer les connaissances protéomiques et faciliter les découvertes et le développement de médicaments · Persbericht

3 september 2025 · Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development · Persbericht

31 juli 2025 · Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025 · Persbericht

30 juli 2025 · Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling · Persbericht

10 juli 2025 · Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025 · Persbericht

10 juli 2025 · Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year · Persbericht

23 juni 2025 · Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy · Persbericht

10 juni 2025 · lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics · Persbericht

29 mei 2025 · Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis · Persbericht

28 mei 2025 · Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies · Persbericht

14 mei 2025 · Illumina To Webcast Upcoming Investor Conference · Persbericht

13 mei 2025 · Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications · Persbericht

8 mei 2025 · Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 · Persbericht

1 mei 2025 · Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development · Persbericht

15 april 2025 · Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation · Persbericht

10 april 2025 · Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 · Persbericht

25 maart 2025 · Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors · Persbericht

19 maart 2025 · Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery · Persbericht

10 maart 2025 · Illumina addresses recent developments in China · Persbericht

6 maart 2025 · Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year · Persbericht

Mijn selecties